US Biotech Seeks Funds for Long Covid Drug Shown to Ease Fatigue

Axcella Health Inc. is seeking funding to carry out an advanced trial of a drug initially found to improve fatigue in long Covid patients.

In a move that could offer hope to the tens of millions of people affected by the condition, the US biotech wants to further study the drug AXA1125 following promising early results, said Chief Executive Officer Bill Hinshaw in an email.

An early-stage trial of the drug with the University of Oxford found participants given the treatment showed a significant improvement in fatigue compared with those in the placebo arm, according to the results published ...